4DMEDICAL FORMERLY KNOWN AS 4Dx

 

Press

Home grown lung tracker biotech 4DMedical has confirmed it expects to hit the ASX boards on August 14th after it completes a $50 million IPO with shares on offer at 73c each. The company's XV Technology platforms helps doctors track respiratory illnesses with more accuracy by...

BREATHING EASIER Brisbane-born entrepreneur Andreas Fouras (illustrated) is poised to radically shake up how doctors around the world diagnose and treat lung ailments. His start-up company 4DMedical announced a $50m IPO on Friday to drive the growth of groundbreaking technology he developed and which he claims is...

Sarah Thompson, Anthony Macdonald and Tim Boyd Jun 29, 2020 – 11:03am When the excitement of bookbuild day comes around, it pays to stay calm and breathe easy. 4DMedical founder Andreas Fouras. Wayne Taylor And in the case of ASX aspirant and lung imaging technology outfit 4DMedical – which is raising $45 million for its...

MAY 26, 2020 BY SEAN WHOOLEY 4DMedical announced that it received FDA clearance for its XV Technology for analyzing functional lung impairment from a single X-ray. Australia-based 4DMedical (formerly 4DX), which has a U.S. base in Woodland Hills, Calif., designed the XV Technology as a four-dimensional lung imaging process in...

Released on May 25, 2020 WOODLAND HILLS, Calif., May 25, 2020 /PRNewswire/ — 4DMedical, an Australian medical technology company specializing in medical imaging innovation software, announced today it has received clearance from the U.S. Food & Drug Administration to market its XV Technology™,  a patented four-dimensional lung imaging  process...

WOODLAND HILLS, Calif., May 25, 2020 /PRNewswire/ -- 4DMedical, an Australian medical technology company specializing in medical imaging innovation software, announced today it has received clearance from the U.S. Food & Drug Administration to market its XV Technology™,  a patented four-dimensional lung imaging  process that rapidly and automatically...